WASHINGTON — CRN applauds FDA’s announcement today to exercise enforcement discretion for qualified health claims regarding magnesium and reduced risk of high blood pressure. The announcement was in response to a petition sponsored by CRN and other organizations filed on behalf of the Center for Magnesium Education and Research LLC, and allows qualified health claims on the relationship between magnesium and a reduced risk of high blood pressure in conventional foods and dietary supplements.

“We are pleased FDA recognizes the role of magnesium in reducing the risk of hypertension in addition to this essential nutrient’s many other functions in the body,” stated Andrea Wong, senior vice president of scientific and regulatory affairs. “CRN’s contribution to the petition is an example of our continued commitment to scientific research to advance regulatory and nutrition policy change.” CRN is the only dietary supplement trade association that supported the petition.